Takeda Oncology Here2Assist^®

Committed to supporting your patients.

Takeda Oncology Here2Assist^® is a comprehensive patient support program that:

Works with your patientsʼ insurance company to help get your patients started on their medication
Identifies available financial assistance that may be right for your patients
Identifies specialty pharmacies to help fill and ship your patientsʼ prescriptions appropriately
Conducts regular follow-ups with patients
Sends text message status updates and reminders to patients^†

DOWNLOAD the Here2Assist BROCHURE

Takeda Oncology Here2Assist^® Case Managers are your patients’ connection to personalized support

Our Case Managers can work with your patients’ insurance companies to conduct benefits verifications^* and create a summary of coverage options for each enrolled patient.

Takeda Oncology Here2Assist Case Managers may provide access support for patients prescribed Takeda Oncology medications by:

Helping patients understand their coverage for their Takeda Oncology medication
Identifying a specialty pharmacy to help fill and ship your patients’ prescriptions appropriately
Identifying available financial assistance that may be right for your patients
Conducting regular follow-ups for support along the way

Enrolling your patients in Takeda Oncology Here2Assist^® is simple

Visit www.Here2Assist.com/hcp and select “Enroll Online.” This is a digital enrollment platform that makes the process easy for you and your patients
Work together with your patient to complete the Enrollment Form and fax it to 1-844-269-3038
Alternatively, your patient can now initiate enrollment digitally. If your patient has submitted a digital enrollment, you will be notified and asked to complete the form via fax or email.

Understanding your patientʼs coverage

After enrollment, a Case Manager will work to determine your patient’s coverage options

Takeda Oncology Here2Assist^® can help your patients navigate coverage requirements by providing information related to:

Benefits verification^*
Prior authorizations^†
Payer denials^†

^*Verification of benefits is not a guarantee of payment and does not take the place of written policy information. Healthcare providers should carry out their own benefits investigation, as necessary.
^†Takeda Oncology Here2Assist^® does not complete forms, file claims, submit prior authorizations or appeal claims on behalf of the physician or caller. Takeda Oncology Here2Assist^® cannot assist with or guarantee success in obtaining final payer approval.

NINLARO^® (ixazomib) is available through both specialty pharmacies and practices that dispense

Provider- or payer-preferred specialty pharmacy
Any specialty pharmacy within the NINLARO^® (ixazomib) network

Choose one of the following specialty pharmacies in the NINLARO^® (ixazomib) network:

Accredo Health Group Inc. 1-877-732-3431
AllianceRx Walgreens Pharmacy 1-888-782-8443
Biologics by McKesson 1-800-850-4306
CVS Specialty 1-800-360-0520
Onco360 Oncology Pharmacy 1-877-662-6633
Optum 1-855-427-4682

In-office dispensing

To arrange in-office dispensing, please contact your specialty distributor or Takeda Oncology Here2Assist^® at 1-844-817-6468, Option 5, Monday-Friday, 8AM-8PM ET

Discover financial assistance available to your patients

Case Managers can help identify financial assistance that may be available to your patients

For patients who are commercially insured and concerned about their out-of-pocket costs, the Takeda Oncology Co-Pay Assistance Program* may be able to help.

HELP YOUR PATIENTS ENROLL TODAY

You or your patient can visit www.takedaoncologycopay.com to confirm program eligibility and enroll
- Upon enrollment, your patient will receive a co-pay card electronically, as well as in the mail. Their card will be valid for a 12-month calendar period and can be renewed on January 1 of the new calendar year with continued program eligibility

^*Terms and Conditions apply.

Takeda Oncology Co-Pay Assistance Program

Your patient could pay as little as $0 per prescription. Terms and Conditions apply^*

For patients who are commercially insured and concerned about their out-of-pocket costs, the Takeda Oncology Co-Pay Assistance Program^* may be able to help. To learn more, visit www.takedaoncologycopay.com.

Your patients can visit www.takedaoncologycopay.com to check eligibility and enroll directly.

*By enrolling in the Takeda Oncology Co-Pay Assistance Program (the “Program”), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:

You must be at least 18 years old, a resident of the United States or a US Territory, and have commercial (private) prescription insurance that does not cover the entire cost of the Takeda Oncology medication. The Program is not valid for patients whose prescription claims for the Takeda Oncology medication are eligible to be reimbursed, in whole or in part, by any state or federal healthcare program, including, but not limited to, Medicare, Medicaid, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, or any state or territory pharmaceutical assistance program. Patients who become eligible for or start using government insurance for their Takeda Oncology medications will no longer be eligible for the Program. The Program is not valid if the entire cost of your prescription is reimbursable by a private insurance plan or other private health or pharmacy benefit programs. You are responsible for reporting receipt of Program assistance to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost, as may be required.

You agree that you will not submit the cost of any portion of the product dispensed pursuant to this Program to a federal or state healthcare program (including, but not limited to, Medicare, Medicaid, TRICARE, VA, DoD, etc.), for purposes of counting it toward your out-of-pocket expenses, and to notify Takeda Oncology Here2Assist^® if you become eligible for a federal or state healthcare program that covers your Takeda Oncology medication. This Program is not conditioned on any past, present or future purchase of any Takeda product, including refills. This Program is valid for up to 12 months, and your co-pay card may be renewed every 12 months, subject to continued eligibility at the beginning of each calendar year. This offer is not valid with any other program, discount, or offer involving your prescribed Takeda Oncology medication. This offer may be rescinded, revoked, or amended without notice. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. No income requirements or membership fees. This Program is not health insurance. Cash value of 1/100 of 1¢. For questions about this offer, please contact the Takeda Oncology Co-Pay Assistance Program, a patient support service of Takeda Oncology Here2Assist, at 1-844-817-6468, Option 2, Monday-Friday, 8AM-8PM ET.

Takeda Oncology Patient Assistance Program^*

If your patient is uninsured or the prescribed medication is not covered, the patient may be eligible to receive their Takeda Oncology medication at no cost through our Patient Assistance Program.^*

To enroll, your patients must first enroll into Takeda Oncology Here2Assist^®. Please visit www.Here2Assist.com to complete the Enrollment Form. A Case Manager will reach out after the enrollment is completed and may be able to identify patient eligibility for available programs. A Case Manager can be reached by calling 1-844-817-6468, Option 2.

If your patient qualifies for the Takeda Oncology Patient Assistance Program, they may be enrolled for up to 1 year. Upon enrollment, a Takeda Oncology Here2Assist Case Manager will notify you and your patient. A 1-month supply of medication will be delivered to your patient at no cost to them. Each month a Takeda Oncology Here2Assist Case Manager will follow up with your patient to confirm that they are still being treated and are eligible to receive another month’s supply of medication.

^*To be eligible for the Patient Assistance Program, patients must meet certain financial and insurance coverage criteria.
A Patient Assistance Program Application must be submitted in order to confirm patient eligibility.

We have resources to help your patients throughout the treatment journey

Takeda Oncology Here2Assist^® Case Managers can provide your patients with information about additional resources that may assist with the day-to-day support they need, including:

Enrollment resources
Provider resources
Patient resources

For more information about patient access support and financial assistance that your patients may qualify for, call us at 1-844-817-6468, Option 2. Let’s Talk. We’re available Monday-Friday, 8AM-8PM ET, or visit us at www.Here2Assist.com/hcp to learn more.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombocytopenia has been reported with NINLARO. Platelet nadirs typically occurred between Days 14-21 of each 28-day cycle and recovered to baseline by the start of the next cycle. Grade 3 thrombocytopenia was reported in 17% of patients in the NINLARO regimen and Grade 4 thrombocytopenia was reported in 13% in the NINLARO regimen. During treatment, monitor platelet counts at least monthly, and consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications and platelet transfusions as per standard medical guidelines.

Gastrointestinal Toxicities, including diarrhea, constipation, nausea and vomiting were reported with NINLARO and may occasionally require the use of antidiarrheal and antiemetic medications, and supportive care. Diarrhea resulted in the discontinuation of one or more of the three drugs in 3% of patients in the NINLARO regimen and 2% of patients in the placebo regimen. Adjust dosing for Grade 3 or 4 symptoms.

Peripheral Neuropathy was reported with NINLARO. The most commonly reported reaction was peripheral sensory neuropathy (24% and 17% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (<1%). Peripheral neuropathy resulted in discontinuation of one or more of the three drugs in 4% of patients in the NINLARO regimen and <1% of patients in the placebo regimen. During treatment, monitor patients for symptoms of neuropathy and consider adjusting dosing for new or worsening peripheral neuropathy.

Peripheral Edema was reported with NINLARO. Evaluate for underlying causes and provide supportive care, as necessary. Adjust dosing of NINLARO for Grade 3 or 4 symptoms or dexamethasone per its prescribing information.

Cutaneous Reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis, including fatal cases, have been reported with NINLARO. If Stevens-Johnson syndrome or toxic epidermal necrolysis occurs, discontinue NINLARO and manage as clinically indicated. Rash, most commonly maculo-papular and macular rash, was reported with NINLARO. Rash resulted in discontinuation of one or more of the three drugs in <1% of patients in both regimens. Manage rash with supportive care or with dose modification if Grade 2 or higher.

Thrombotic Microangiopathy has been reported with NINLARO. Fatal cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in patients who received NINLARO. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop NINLARO and evaluate. If the diagnosis of TTP/HUS is excluded, consider restarting NINLARO. The safety of reinitiating NINLARO therapy in patients previously experiencing TTP/HUS is not known.

Hepatotoxicity has been reported with NINLARO. Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have each been reported in <1% of patients treated with NINLARO. Hepatotoxicity has been reported (10% in the NINLARO regimen and 9% in the placebo regimen). Monitor hepatic enzymes regularly and adjust dosing for Grade 3 or 4 symptoms.

Embryo-fetal Toxicity: NINLARO can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with NINLARO and for 90 days following the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with NINLARO and for 90 days following the last dose.

Increased Mortality in Patients Treated with NINLARO in the Maintenance Setting: In two prospective randomized clinical trials in multiple myeloma in the maintenance setting, treatment with NINLARO resulted in increased deaths. Treatment of patients with NINLARO for multiple myeloma in the maintenance setting is not recommended outside of controlled trials.

ADVERSE REACTIONS

The most common adverse reactions (≥ 20%) in the NINLARO regimen compared to placebo in combination with lenalidomide plus dexamethasone, respectively were thrombocytopenia (85%, 67%; pooled from adverse event and laboratory data), neutropenia (74%, 70%; pooled from adverse event and laboratory data), diarrhea (52%, 43%), constipation (35%, 28%), peripheral neuropathy (32%, 24%), nausea (32%, 23%), edema peripheral (27%, 21%), rash (27%, 16%), vomiting (26%, 13%), and bronchitis (22%, 17%). Serious adverse reactions reported in ≥ 2% of patients in the NINLARO regimen included diarrhea (3%), thrombocytopenia (2%), and bronchitis (2%).

DRUG INTERACTIONS:

Avoid concomitant administration of NINLARO with strong CYP3A inducers.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during treatment with NINLARO and for 90 days after the last dose.

Hepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.

Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease requiring dialysis. NINLARO is not dialyzable.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-217-6468 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Takeda Oncology Here2Assist^®

Takeda Oncology Here2Assist^® is a comprehensive patient support program that:

Takeda Oncology Here2Assist^® Case Managers are your patients’ connection to personalized support

Enrolling your patients in Takeda Oncology Here2Assist^® is simple

Understanding your patientʼs coverage

NINLARO^® (ixazomib) is available through both specialty pharmacies and practices that dispense

Discover financial assistance available to your patients

Takeda Oncology Co-Pay Assistance Program

Takeda Oncology Patient Assistance Program^*

We have resources to help your patients throughout the treatment journey

IMPORTANT SAFETY INFORMATION, INDICATION, AND USAGE

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS

INDICATION AND USAGE

Takeda Oncology Here2Assist® is a comprehensive patient support program that:

Takeda Oncology Here2Assist® Case Managers are your patients’ connection to personalized support

Enrolling your patients in Takeda Oncology Here2Assist® is simple

Understanding your patientʼs coverage

NINLARO® (ixazomib) is available through both specialty pharmacies and practices that dispense

Discover financial assistance available to your patients

Takeda Oncology Co-Pay Assistance Program

Takeda Oncology Patient Assistance Program*

We have resources to help your patients throughout the treatment journey

IMPORTANT SAFETY INFORMATION, INDICATION, AND USAGE

Takeda Oncology Here2Assist^® is a comprehensive patient support program that:

Takeda Oncology Here2Assist^® Case Managers are your patients’ connection to personalized support

Enrolling your patients in Takeda Oncology Here2Assist^® is simple

NINLARO^® (ixazomib) is available through both specialty pharmacies and practices that dispense

Takeda Oncology Patient Assistance Program^*